These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26343256)

  • 21. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.
    Chang M; Tybring G; Dahl ML; Lindh JD
    Clin Pharmacokinet; 2014 Sep; 53(9):801-11. PubMed ID: 25154506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.
    Román M; Ochoa D; Sánchez-Rojas SD; Talegón M; Prieto-Pérez R; Rivas Â; Abad-Santos F; Cabaleiro T
    Pharmacogenomics; 2014; 15(15):1893-901. PubMed ID: 25495411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation.
    Baumann P; Nil R; Souche A; Montaldi S; Baettig D; Lambert S; Uehlinger C; Kasas A; Amey M; Jonzier-Perey M
    J Clin Psychopharmacol; 1996 Aug; 16(4):307-14. PubMed ID: 8835706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2C19 variation and citalopram response.
    Mrazek DA; Biernacka JM; O'Kane DJ; Black JL; Cunningham JM; Drews MS; Snyder KA; Stevens SR; Rush AJ; Weinshilboum RM
    Pharmacogenet Genomics; 2011 Jan; 21(1):1-9. PubMed ID: 21192344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.
    Zand N; Tajik N; Moghaddam AS; Milanian I
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):102-5. PubMed ID: 17201743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem.
    Byeon JY; Kim YH; Kim SH; Lee CM; Jung EH; Chae WK; Jang CG; Lee SY; Lee YJ
    Arch Pharm Res; 2018 Aug; 41(8):861-866. PubMed ID: 30117082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer.
    Kattel K; Evande R; Tan C; Mondal G; Grem JL; Mahato RI
    Br J Clin Pharmacol; 2015 Aug; 80(2):267-75. PubMed ID: 25752914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRP1 polymorphisms associated with citalopram response in patients with major depression.
    Lee SH; Lee MS; Lee JH; Kim SW; Kang RH; Choi MJ; Park SJ; Kim SJ; Lee JM; Cole SP; Lee MG
    J Clin Psychopharmacol; 2010 Apr; 30(2):116-25. PubMed ID: 20520284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between the serotonin 2A receptor gene -1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients.
    Demirbugen Oz M; Uckun Z; Yuce-Artun N; Baskak B; Ozdemir H; Kizil Ozel T; Devrimci Ozguven H; Suzen HS
    Hum Psychopharmacol; 2018 Sep; 33(5):e2673. PubMed ID: 30221791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of genetic polymorphisms of drug metabolizing enzymes on the pharmacodynamics of clopidogrel under steady state conditions.
    Nakkam N; Tiamkao S; Kanjanawart S; Tiamkao S; Vannaprasaht S; Tassaneeyakul W; Tassaneeyakul W
    Drug Metab Pharmacokinet; 2015 Aug; 30(4):295-304. PubMed ID: 26099919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
    Taranu A; Colle R; Gressier F; El Asmar K; Becquemont L; Corruble E; Verstuyft C
    Pharmacogenomics; 2017 May; 18(7):639-650. PubMed ID: 28480819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
    Taur SR; Kulkarni NB; Gandhe PP; Thelma BK; Ravat SH; Gogtay NJ; Thatte UM
    J Postgrad Med; 2014; 60(3):265-9. PubMed ID: 25121365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography.
    Rochat B; Amey M; Baumann P
    Ther Drug Monit; 1995 Jun; 17(3):273-9. PubMed ID: 7624924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of CYP2C19 gene polymorphism on warfarin maintenance doses in patients with non-valvular atrial fibrillation.
    Zhang H; Ma K; Liu W; Yang F; Liu J; Zhou H
    Gene; 2016 Oct; 591(1):80-84. PubMed ID: 27356304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of genetic polymorphisms of CYP2C19*2/*3 and MDR1 C3435T on the pharmacokinetics of lansoprazole in healthy Chinese subjects.
    Zhang YX; Wei SJ; Yang XY; Zhang WP; Wang XY; Dang HW
    Int J Clin Pharmacol Ther; 2014 Oct; 52(10):850-5. PubMed ID: 25109411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABCB1 C3435T polymorphism is associated with susceptibility to major depression, but not with a clinical response to citalopram in a Turkish population.
    Ozbey G; Yucel B; Taycan SE; Kan D; Bodur NE; Arslan T; Percin F; Yuksel N; Guzey C; Uluoglu C
    Pharmacol Rep; 2014 Apr; 66(2):235-8. PubMed ID: 24911075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip.
    Sameer AE; Amany GM; Abdela AA; Fadel SA
    Can J Clin Pharmacol; 2009; 16(1):e156-62. PubMed ID: 19193970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.
    Jin Y; Pollock BG; Frank E; Cassano GB; Rucci P; Müller DJ; Kennedy JL; Forgione RN; Kirshner M; Kepple G; Fagiolini A; Kupfer DJ; Bies RR
    J Clin Pharmacol; 2010 Jan; 50(1):62-72. PubMed ID: 19841156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.